Correction to: CB1 Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling, by Gamage TF, Anderson JC, and Abood ME. Cannabis Cannabinoid Res. 2016;1(1):272–280. DOI: 10.1089/can.2016.0028;CB1 Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 272-280

  Gamage, Thomas F ^a   Anderson, Johnathon C ^a   Abood, Mary E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

allosteric; cannabinoid; CB1; ERK; Org27569; signaling

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ORG 27569; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SCREENING; EMBRYO; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; INTERNALIZATION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 85025434756     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2016.0028.correx     Document Type: Erratum

References (41)

1. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
3. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
4. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor-ligand in brain. Biochem Biophys Res Commun. 1995;215:89-97.
5. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 2009;60:77-84.
6. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.
7. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 1992;106:231-232.
8. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A. 1992;89:3825-3829.
9. Gamage, et al.; Cannabis and Cannabinoid Research 2016, 1.1 http://online.liebertpub.com/doi/10.1089/can.2016.0028 279
10. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78:43-50.
11. Guo J, Ikeda SR. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol Pharmacol. 2004;65:665-674.
12. Bouaboula M, Poinot-Chazel C, Bourrie B, et al. Activation of mitogenactivated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J. 1995;312(Pt 2):637-641.
13. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther. 2011;336:296-302.
14. Khajehali E, Malone DT, Glass M, et al. Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol Pharmacol. 2015;88:368-379.
15. Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005;68:1484-1495.
16. Horswill JG, Bali U, Shaaban S, et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol. 2007;152:805-814.
17. Pamplona FA, Ferreira J, de Lima OM, et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci U S A. 2012;109:21134-21139.
18. Navarro HA, Howard JL, Pollard GT, et al. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol. 2009;156:1178-1184.
19. Ignatowska-Jankowska BM, Baillie GL, Kinsey S, et al. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology. 2015;40:2948-2959.
20. Bauer M, Chicca A, Tamborrini M, et al. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 2012;287:36944-36967.
21. Baillie GL, Horswill JG, Anavi-Goffer S, et al. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol. 2013;83:322-338.
22. Shore DM, Baillie GL, Hurst DH, et al. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem. 2014;289:5828-5845.
23. Cawston EE, Redmond WJ, Breen CM, et al. Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol. 2013;170:893-907.
24. Ahn KH, Mahmoud MM, Shim JY, et al. Distinct roles of beta-arrestin 1 and beta-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem. 2013;288:9790-9800.
25. Dalton GD, Howlett AC. Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells. Br J Pharmacol. 2012;165:2497-2511.
26. Daigle TL, Kearn CS, Mackie K. Rapid CB 1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology. 2008;54:36-44.
27. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66:105-143.
28. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004;5:173-183.
29. Rubino T, Forlani G, Vigano D, et al. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem. 2005;93:984-991.
30. Rinaldi-Carmona M, Le Duigou A, Oustric D, et al. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharm Exp Ther. 1998;287:1038-1047.
31. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 Evidence for a new model of receptor/ligand interactions. J Biol Chem. 1997;272:22330-22339.
32. Chen X, Yang W, Fan Y, et al. Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to Gs and Gi. Br J Pharmacol. 2010;161:1817-1834.
33. Tao Q, McAllister SD, Andreassi J, et al. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol Pharmacol. 1999;55:605-613.
34. Tohgo A, Pierce KL, Choy EW, et al. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J Biol Chem. 2002;277:9429-9436.
35. Ahn KH, Mahmoud MM, Kendall DA. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem. 2012;287:12070-12082.
36. Korzh A, Keren O, Gafni M, et al. Modulation of extracellular signalregulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Res. 2008;1189:23-32.
37. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB 1 receptors. Life Sci. 2005;76:1307-1324.
38. Atwood BK, Lopez J, Wager-Miller J, et al. Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics. 2011;12:14.
39. Landsman RS, Burkey TH, Consroe P, et al. SR141716A is an inverse agonist at the human cannabinoid CB 1 receptor. Eur J Pharmacol. 1997;334:R1-R2.
40. Meschler JP, Kraichely DM, Wilken GH, et al. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB 1 cannabinoid receptor. Biochem Pharmacol. 2000;60:1315-1323.
41. Mato S, Pazos A, Valdizan EM. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur J Pharmacol. 2002;443:43-46.